You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

208 Results
Regimen
Intent: Adjuvant
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer
Feb 2022
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Intent: Palliative
Apr 2018
Regimen
Cancer Type:
Gynecologic, 
Endometrial, 
Ovary
Intent: Palliative
Funding:
ODB - General Benefit
    tamoxifen
May 2022
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Pertuzumab with Trastuzumab (Biosimilar) - Unresectable Locally Recurrent or Metastatic Breast Cancer
New Drug Funding Program
    Pertuzumab with Trastuzumab (Biosimilar) - Unresectable Locally Recurrent or Metastatic Breast Cancer
Sep 2022
Regimen
Intent: Adjuvant
Feb 2018
Regimen
Intent: Palliative
Oct 2022
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
ODB Limited Use
    lenalidomide - For the maintenance treatment of patients with newly diagnosed multiple myeloma, following ASCT, according to clinical criteria
May 2022
Regimen
Cancer Type:
Gynecologic, 
Cervix
Intent: Palliative
Funding:
New Drug Funding Program
    Bevacizumab (Biosimilar) - Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix
Apr 2022
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Palliative
Sep 2022
Regimen
Cancer Type:
Gynecologic, 
Vulva
Intent: Palliative
Oct 2022
Regimen
Cancer Type:
Gynecologic, 
Uterine Sarcoma, 
Sarcoma, 
Soft Tissue, 
Uterine
Intent: Palliative
Jul 2018

Pages